Soleno Therapeutics stock overview

Soleno Therapeutics (SLNO) has drawn investor attention after recent share performance, with the stock showing a one-month return of 34.01% and a three-month return of 25.64%.

That recent momentum sits against a mixed longer record, with a 34.01% 1 month share price return and 25.64% 3 month share price return contrasting with a 28.21% 1 year total shareholder return decline but a very large 3 year total shareholder return.

If you are curious about what else is moving around healthcare and biotech right now, it could be a good time to scan 35 healthcare AI stocks

With Soleno trading around $52.92 and almost in line with an analyst price target of $53.00, plus a very large 3 year total return already on the board, investors may be wondering whether there is still a buying opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 53.4% Undervalued

Soleno Therapeutics' most followed narrative points to a fair value of $113.54, which sits well above the last close of $52.92 and frames the current debate around the stock.

Rapid uptake of VYKAT XR as the first and only FDA approved treatment for PWS related hyperphagia, with more than 1,000 patient start forms and 764 active patients within six months, supports a path to sustained revenue growth as penetration into an estimated 10,000 patient U.S. market increases.

Curious what kind of revenue build, margin profile and future earnings power sit behind that view? The narrative leans on aggressive growth, sharply higher profitability and a valuation multiple that assumes the story matures without stalling.

Result: Fair Value of $113.54 (UNDERVALUED)

However, this hinges on launch momentum holding up and safety perceptions staying stable, as slower patient uptake or higher discontinuations could quickly challenge the optimistic fair value story.

Another view on valuation

The narrative built around analyst targets paints Soleno as heavily undervalued, yet the current P/E of 133.7x tells a very different story. That is far above the US Biotechs average of 17.2x and well above a fair ratio of 25.8x, which points to meaningful valuation risk if expectations slip.

For investors who prefer to anchor on earnings based yardsticks, this kind of gap between current P/E, peers and the fair ratio can be a useful reality check on how much optimism is already in the price. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly mixed, you may want to review the full picture for yourself. You can check the data on 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Soleno has your attention, do not stop here. Use this momentum to scan other opportunities that could fit your goals and broaden your watchlist.

• Target higher quality potential by reviewing 51 high quality undervalued stocks that combine strong fundamentals with prices that do not fully reflect their metrics.
• Prioritise resilience with 72 resilient stocks with low risk scores that aim to keep overall portfolio volatility in check.
• Hunt for underfollowed opportunities through the screener containing 25 high quality undiscovered gems before they attract broader attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.